HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
KCNS1
potassium voltage-gated channel modifier subfamily S member 1
Chromosome 20 · 20q13.12
NCBI Gene: 3787Ensembl: ENSG00000124134.9HGNC: HGNC:6300UniProt: A2RUL8
15PubMed Papers
20Diseases
7Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
regulation of potassium ion transmembrane transportplasma membranevoltage-gated potassium channel complexprotein bindingmultiple sclerosisMyasthenia gravisLambert-Eaton myasthenic syndromeMuscle weakness
✦AI Summary

KCNS1 (Kv9.1) is a voltage-gated potassium channel regulatory subunit that modulates delayed rectifier potassium channel activity by assembling into functional heterotetrameric complexes with KCNB1 (Kv2.1) and KCNB2 (Kv2.2) 1. The protein does not form functional channels independently but alters kinetics, expression levels, and half-inactivation potentials of partner channels 1, 2. KCNS1 is predominantly expressed in myelinated sensory neurons, including Aδ-fiber nociceptors and Aβ mechanoreceptors, as well as spinal dorsal horn and motoneurons 3. Functionally, KCNS1 regulates nociceptive excitability; mice lacking peripheral Kcns1 exhibit increased basal and neuropathic pain sensitivity with exaggerated mechanical and cold pain responses 3. Genetically, the KCNS1 rs734784 A>G variant marginally increases chr20 postsurgical pain risk (OR: 1.511) 4, and KCNS1 variation predicts pain sensitivity and chr20 pain risk in humans 5. Additionally, KCNS1 expression correlates with cortical developmental patterns and gene expression changes in psychiatric disorders during pubertal transition 6. These findings establish KCNS1 as a key regulator of neuronal excitability with significant implications for pain management and neurodevelopmental disorders.

Sources cited
1
KCNS1 modulates KCNB1/KCNB2 channel activity and can form functional heterotetrameric channels
PMID: 10484328
2
KCNS1 (Kv9.1) forms functional heteromeric channels with Kv2 subunits and contributes to neuronal conductances
PMID: 40423692
3
KCNS1 is expressed in nociceptors and mechanoreceptors; peripheral Kcns1 ablation increases basal and neuropathic pain sensitivity
PMID: 29697531
4
KCNS1 rs734784 G allele marginally increases chronic postsurgical pain risk
PMID: 31129315
5
KCNS1 gene variation predicts pain sensitivity and risk for persistent pain
PMID: 25872119
6
KCNS1 expression correlates with cortical thickness patterns in development and psychiatric disorders
PMID: 36380235
Disease Associationsⓘ20
multiple sclerosisOpen Targets
0.59Moderate
Myasthenia gravisOpen Targets
0.56Moderate
Lambert-Eaton myasthenic syndromeOpen Targets
0.55Moderate
Muscle weaknessOpen Targets
0.46Moderate
congenital myasthenic syndromeOpen Targets
0.43Moderate
Congenital myasthenic syndromesOpen Targets
0.43Moderate
cancerOpen Targets
0.37Weak
neoplasmOpen Targets
0.37Weak
autoimmune diseaseOpen Targets
0.37Weak
autoimmune disorder of the nervous systemOpen Targets
0.37Weak
cardiac arrhythmiaOpen Targets
0.37Weak
immune system diseaseOpen Targets
0.37Weak
Increased muscle fatiguabilityOpen Targets
0.37Weak
nervous system diseaseOpen Targets
0.37Weak
nervous system neoplasmOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.37Weak
neuromuscular diseaseOpen Targets
0.37Weak
neuromuscular junction diseaseOpen Targets
0.37Weak
paraneoplastic neurologic syndromeOpen Targets
0.37Weak
small cell carcinomaOpen Targets
0.37Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets7
AMIFAMPRIDINEApproved
Voltage-gated potassium channel blocker
Myasthenia gravis
AMIFAMPRIDINE PHOSPHATEApproved
Voltage-gated potassium channel blocker
Lambert-Eaton myasthenic syndrome
DALFAMPRIDINEApproved
Voltage-gated potassium channel blocker
multiple sclerosis
GUANIDINEPhase III
Voltage-gated potassium channel blocker
neuroendocrine neoplasm
GUANIDINE HYDROCHLORIDEApproved
Voltage-gated potassium channel blocker
Myasthenia gravis
NERISPIRDINEPhase II
Voltage-gated potassium channel blocker
multiple sclerosis
TEDISAMILApproved
Voltage-gated potassium channel blocker
cardiac arrhythmia
Related Genes
KCNS3Shared pathway100%FAUProtein interaction91%KCNK15Protein interaction86%KCNG1Shared pathway86%KCNG4Shared pathway86%KCNG3Shared pathway86%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
16%
Heart
1%
Lung
1%
Liver
0%
Ovary
0%
Gene Interaction Network
Click a node to explore
KCNS1KCNS3FAUKCNK15KCNG1KCNG4KCNG3
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q96KK3
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.31LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.96 [0.71–1.31]
RankingsWhere KCNS1 stands among ~20K protein-coding genes
  • #15,599of 20,598
    Most Researched15
  • #342of 1,025
    FDA-Approved Drug Targets5
  • #13,810of 17,882
    Most Constrained (LOEUF)1.31
Genes detectedKCNS1
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain.
PMID: 31129315
J Pain · 2020
1.00
2
A Kv2 inhibitor combination reveals native neuronal conductances consistent with Kv2/KvS heteromers.
PMID: 40423692
Elife · 2025
0.90
3
Mice lacking Kcns1 in peripheral neurons show increased basal and neuropathic pain sensitivity.
PMID: 29697531
Pain · 2018
0.80
4
Emerging potassium channel targets for the treatment of pain.
PMID: 25872119
Curr Opin Support Palliat Care · 2015
0.70
5
Cortical profiles of numerous psychiatric disorders and normal development share a common pattern.
PMID: 36380235
Mol Psychiatry · 2023
0.60